NTRA - ナテラ (Natera Inc.) ナテラ

 NTRAのチャート


 NTRAの企業情報

symbol NTRA
会社名 Natera Inc (ナテラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ナテラ(Natera Inc.)は診断会社である。同社は遺伝子検査サービスの発見・開発・商品化に従事する。同社は、母親から採血した胎児の染色体異常をスクリーニングするパノラマ非侵襲性出生前検査、キャリアの子供に渡される可能性のある多数の重度の遺伝病のキャリアステータスを決定するホライゾンキャリアスクリーニング、体外受精サイクル中に染色体異常または遺伝的遺伝的状態を分析して健康な子供になる可能性のある胚を選択するスペクトラムプレ移植遺伝子スクリーニングとスペクトラムプレ移植遺伝子診断、流産の原因を理解するために胎児の染色体を分析する受胎テストのAnora製品、並びに妊娠している母親の血液中の胎児性デオキシリボ核酸の断片と、疑わしい父親由来の血液サンプルを分析することにより父性を決定する非侵襲性父性検査を提供する。   ナテラは米国の遺伝子検査サ―ビス会社。主に出生前の遺伝子検査を提供する。体外受精において、着床前遺伝子スクリ―ニングを提供し、染色体異常や遺伝性遺伝子の状態を解析することで、受精胚の選択を可能にする。また、胎児の染色体異常を発見する検査や実父確定検査なども提供する。本社はカリフォルニア州サンカルロス。   
本社所在地 201 Industrial Road Suite 410 San Carlos CA 94070 USA
代表者氏名 Matthew Rabinowitz マシュー・ラビノウィッツ
代表者役職名 Chairman of the Board President Chief Executive Officer Co-Founder
電話番号 +1 650-249-9090
設立年月日 37926
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 893人
url www.natera.com
nasdaq_url https://www.nasdaq.com/symbol/ntra
adr_tso
EBITDA EBITDA(百万ドル) -120.49200
終値(lastsale) 21.31
時価総額(marketcap) 1298720475.8
時価総額 時価総額(百万ドル) 1225.587
売上高 売上高(百万ドル) 235.83000
企業価値(EV) 企業価値(EV)(百万ドル) 1265.723
当期純利益 当期純利益(百万ドル) -139.31800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Natera Inc revenues increased 23% to $125.4M. Net loss increased 7% to $66.7M. Revenues reflect United States segment increase of 21% to $107M Europe Middle East India Africa segment increase of 91% to $13.1M. Higher net loss reflects Interest and other income decrease from $887K (income) to $3.8M (expense) Interest expense increase from $401K to $4.9M (expense).

 NTRAのテクニカル分析


 NTRAのニュース

   U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent  2020/12/18 14:03:00 Benzinga
SAN CARLOS, Calif. , Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA ), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a patentability challenge from a multi-national sequencing company against Natera's U.S. Patent No. 8,682,592 ('592 Patent) upholding all claims. Natera's '592 Patent claims early and significant innovations directed to generating genetic data from limited quantities of DNA, including cfDNA. Natera has shown the techniques to be useful in a variety of contexts such as non-invasive prenatal testing, ctDNA molecular residual disease testing in oncology, and donor-derived cfDNA assessment in organ transplant recipients. In upholding the … Full story available on Benzinga.com
   New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial  2020/12/09 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will be presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in an oral…
   Natera to Present New Immunotherapy Monitoring Data at SABCS 2020  2020/12/08 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera,™ at the 2020 virtual San…
   Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies  2020/12/03 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all…
   Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies  2020/12/01 15:32:00 PR Newswire
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. The expanded coverage comes only a few…
   New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial  2020/12/09 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will be presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in an oral…
   Natera to Present New Immunotherapy Monitoring Data at SABCS 2020  2020/12/08 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera,™ at the 2020 virtual San…
   Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies  2020/12/03 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all…
   Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies  2020/12/01 15:32:00 PR Newswire
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. The expanded coverage comes only a few…
   Natera Appoints Dr. Monica Bertagnolli to its Board of Directors  2020/11/19 14:03:00 PR Newswire
SAN CARLOS, Calif., Nov. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. Monica Bertagnolli to its board of directors. "We are delighted to welcome Dr. Bertagnolli to our board at this…
   New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial  2020/12/09 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will be presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in an oral…
   Natera to Present New Immunotherapy Monitoring Data at SABCS 2020  2020/12/08 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera,™ at the 2020 virtual San…
   Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies  2020/12/03 14:03:00 PR Newswire
SAN CARLOS, Calif., Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all…
   Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies  2020/12/01 15:32:00 PR Newswire
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. The expanded coverage comes only a few…
   Natera Appoints Dr. Monica Bertagnolli to its Board of Directors  2020/11/19 14:03:00 PR Newswire
SAN CARLOS, Calif., Nov. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. Monica Bertagnolli to its board of directors. "We are delighted to welcome Dr. Bertagnolli to our board at this…

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ナテラ NTRA Natera Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)